Trial · NCT06016556
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 40
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Classified According to Education Level at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Education level classification: no formal education, primary school, secondary school, undergraduate university degree, master's degree and Doctor of Philosophy (PhD) or doctorate. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Employment Status at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Employment status classification: full-time employment, part-time employment, homemaker, retired, student, disabled/too ill to work, and unemployed. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Height at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Weight at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Body Mass Index (BMI) at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | BMI was calculated based on the reported weight and height in the unit of kilograms over squared meters (kg/m\^2). Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Smoking Status at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Smoking status classification: current smoker, former smoker and never smoker. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Had at Least 1 Pre-existing Comorbidity at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Had at Least 1 Concomitant Medication for Comorbidities at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants With COVID-19 Infection During the Last 6 Months Prior to Index Date | During 6 months prior to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Duration Between Last COVID-19 Infection and Index Date | From 6 months prior to index date up to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Duration (in months) between COVID-19 infection in last 6 months prior to index date and index date was reported in this outcome measure. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Had Previously Received at Least 1 Dose of Any COVID-19 Vaccine | Historic information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to the Type of COVID-19 Vaccine Received Previously | Historic information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | One participant could have received more than one type of vaccine. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Duration Between Previous COVID-19 Vaccination Date and Index Date | From date of first COVID-19 vaccination to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Duration (in months) between vaccination date and index date was calculated as (index date - date of first covid-19 vaccination date)/30.42. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Total Number of Previous COVID-19 Vaccine Doses Taken | Historic information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Dose of Nirmatrelvir/Ritonavir Received at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Classification: 1) Nirmatrelvir at a dose of 300 milligrams (mg), as 2 split doses of 150 mg and Ritonavir at a dose of 100 mg; 2) Other: Nirmatrelvir at a dose of 150 mg, and Ritonavir at a dose of 100 mg. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Frequency of Dosing of Nirmatrelvir/Ritonavir (PAXLOVIDTM) at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Classification: 1) Nirmatrelvir at a dose of 300 mg, as 2 split doses of 150 mg and Ritonavir at a dose of 100 mg; 2) Other: Nirmatrelvir at a dose of 150 mg, and Ritonavir at a dose of 100 mg. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Dispensed Type of Nirmatrelvir/Ritonavir (PAXLOVIDTM) at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Classification of dispensed type: blister, box, tablets. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Medications Used to Treat COVID-19 Infection at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Number of participants classified according to medications (apart from Nirmatrelvir/Ritonavir \[PAXLOVIDTM\]) used to treat COVID-19 infection at index date were reported in this outcome measure. A participant may receive more than one medication to treat COVID-19 infection. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Were Hospitalized at Index Date | Information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | In this outcome measure those number of participants are reported who were prescribed Nirmatrelvir/Ritonavir (PAXLOVIDTM) while they were hospitalized (related or non-related to COVID-19). Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Were Hospitalized Due to COVID-19 at Index Date | Information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | In this outcome measure those number of participants are reported who were prescribed Nirmatrelvir/Ritonavir (PAXLOVIDTM) while they were hospitalized (related to COVID-19). Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06016556/registered